Aoki S, Kurosawa M, Ishizuka T, Mori M
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Nov;30(11):1946-50.
The present studies were conducted to investigate whether or not VIP and PHI have a bronchodilator effect in vivo. VIP or PHI was administered intravenously in guinea pigs, and dynamic respiratory resistance was measured. Intravenous administration of VIP and PHI reduced dynamic respiratory resistance; however, the effect was significantly less than that of isoprenaline. VIP and PHI inhibited the increase in dynamic respiratory resistance by intravenous administration of histamine in a dose-dependent manner, suggesting that VIP and PHI may be involved in the pathogenesis of airway hyperresponsiveness through inhibiting the effect of mediators on the airway.
进行本研究以调查血管活性肠肽（VIP）和胰高血糖素样肽（PHI）在体内是否具有支气管扩张作用。将VIP或PHI静脉注射给豚鼠，并测量动态呼吸阻力。静脉注射VIP和PHI可降低动态呼吸阻力；然而，其作用明显小于异丙肾上腺素。VIP和PHI以剂量依赖的方式抑制静脉注射组胺引起的动态呼吸阻力增加，表明VIP和PHI可能通过抑制介质对气道的作用而参与气道高反应性的发病机制。
